Articles dans des revues avec comité de lecture (396)
385.
Awada, A., Van Vreckem, A., Paridaens, R., Bruning, P., Klijn, J., Tomiak, E., Vinholes, J., Roy, J., Kusenda, Z., Hoctin Boes, G., van Glabbeke, M., & Piccart-Gebhart, M. (1997). EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): 5 years of European collaboration in new drug development for breast cancer. European journal of cancer, 33(8), 1173-1176. doi:10.1016/S0959-8049(97)00085-3386.
Piccart-Gebhart, M., Bruning, P., Gamucci, T., Klijn, J. G., Roy, J. A., Awada, A., Kusenda, Z., Van Vreckem, A., & Paridaens, R. (1996). An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer. Seminars in oncology, 23(5 Suppl 11), 11-15.388.
Piccart-Gebhart, M., Bruning, P., Wildiers, J., Awada, A., Schornagel, J. H., Thomas, J., Tomiak, E., Bartholomeus, S., Witteveen, P. O., & Paridaens, R. (1995). An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer. Annals of oncology, 6(7), 673-677.389.
Burris, H. A., Awada, A., Kuhn, J., Eckardt, J. R., Cobb, P. W., Rinaldi, D. A., Fields, S., Smith, L., & Von Hoff, D. D. (1994). Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anti-cancer drugs, 5(4), 394-402.390.
Tomiak, E., Piccart-Gebhart, M., Kerger, J., Lips, S., Awada, A., de Valeriola, D., Ravoet, C., Lossignol, D., Sculier, J.-P., Auzannet, V., Le Bail, N., Bayssas, M., & Klastersky, J. (1994). Phase I study of Taxotere administered as a 1-hour intravenous infusion on a weekly basis. Journal of clinical oncology, 12(7), 1458-1467.392.
Luce, S., Awada, A., Gil, T., Kerger, J., de Valeriola, D., Bartholomeus, S., Parmentier, N., Bleiberg, H., Gerard, B., & Piccart-Gebhart, M. (1993). Etude de phase I d’un nouvel agent réverseur de la résistance multidrogue, le S9788, administré seul et en association avec l’Adriamycine. Bulletin du cancer, 80(6), 446.394.
Awada, A., Van Der Auwera, P., Meunier, F., Daneau, D., & Klastersky, J. (1992). Streptococcal and enterococcal bacteremia in patients with cancer. Clinical infectious diseases, 15(1), 33-48.396.
Awada, A., Van Der Auwera, P., Meunier, F., Daneau, D., & Klastersky, J. (1992). Streptococcal and enterococcal bacteremia in patients with cancer. Clinical infectious diseases, 15(1), 33-48.